Barclays PLC Has $255,000 Stock Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS)

Barclays PLC grew its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 280.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 167,718 shares of the company’s stock after purchasing an additional 123,683 shares during the quarter. Barclays PLC owned about 0.13% of Atossa Therapeutics worth $255,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in ATOS. Bank of New York Mellon Corp raised its holdings in Atossa Therapeutics by 3,160.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after purchasing an additional 399,041 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Atossa Therapeutics by 11.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock worth $1,846,000 after purchasing an additional 164,540 shares during the last quarter. Rhumbline Advisers bought a new stake in shares of Atossa Therapeutics in the 2nd quarter valued at $161,000. State Street Corp increased its stake in shares of Atossa Therapeutics by 4.2% in the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company’s stock valued at $2,633,000 after acquiring an additional 69,180 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Atossa Therapeutics in the 3rd quarter valued at $75,000. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Price Performance

ATOS opened at $1.01 on Monday. The company has a market capitalization of $127.06 million, a price-to-earnings ratio of -4.59 and a beta of 1.26. The firm’s fifty day moving average price is $1.22 and its two-hundred day moving average price is $1.30. Atossa Therapeutics, Inc. has a 1 year low of $0.77 and a 1 year high of $2.31.

Analyst Ratings Changes

ATOS has been the subject of several research analyst reports. Ascendiant Capital Markets lifted their price objective on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 9th. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Atossa Therapeutics in a research note on Thursday, December 12th. Finally, StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.